Arterial thromboembolism in cancer patients treated with cisplatin

A systematic review and meta-analysis

Tracy Proverbs-Singh, Sophia K. Chiu, Ziyue Liu, Sonia Seng, Guru Sonpavde, Toni K. Choueiri, Che Kai Tsao, Menggang Yu, Noah Hahn, William K. Oh, Matthew D. Galsky

Research output: Contribution to journalArticle

Abstract

Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

Original languageEnglish (US)
Pages (from-to)1837-1840
Number of pages4
JournalJournal of the National Cancer Institute
Volume104
Issue number23
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Thromboembolism
Cisplatin
Meta-Analysis
Confidence Intervals
Neoplasms
Incidence
Drug Therapy
PubMed
Randomized Controlled Trials
Retrospective Studies
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Proverbs-Singh, T., Chiu, S. K., Liu, Z., Seng, S., Sonpavde, G., Choueiri, T. K., ... Galsky, M. D. (2012). Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal of the National Cancer Institute, 104(23), 1837-1840. https://doi.org/10.1093/jnci/djs435

Arterial thromboembolism in cancer patients treated with cisplatin : A systematic review and meta-analysis. / Proverbs-Singh, Tracy; Chiu, Sophia K.; Liu, Ziyue; Seng, Sonia; Sonpavde, Guru; Choueiri, Toni K.; Tsao, Che Kai; Yu, Menggang; Hahn, Noah; Oh, William K.; Galsky, Matthew D.

In: Journal of the National Cancer Institute, Vol. 104, No. 23, 12.2012, p. 1837-1840.

Research output: Contribution to journalArticle

Proverbs-Singh, T, Chiu, SK, Liu, Z, Seng, S, Sonpavde, G, Choueiri, TK, Tsao, CK, Yu, M, Hahn, N, Oh, WK & Galsky, MD 2012, 'Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis', Journal of the National Cancer Institute, vol. 104, no. 23, pp. 1837-1840. https://doi.org/10.1093/jnci/djs435
Proverbs-Singh, Tracy ; Chiu, Sophia K. ; Liu, Ziyue ; Seng, Sonia ; Sonpavde, Guru ; Choueiri, Toni K. ; Tsao, Che Kai ; Yu, Menggang ; Hahn, Noah ; Oh, William K. ; Galsky, Matthew D. / Arterial thromboembolism in cancer patients treated with cisplatin : A systematic review and meta-analysis. In: Journal of the National Cancer Institute. 2012 ; Vol. 104, No. 23. pp. 1837-1840.
@article{cab640bf89754580bdb268dc7340d366,
title = "Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis",
abstract = "Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95{\%} confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67{\%} (95{\%} CI 0.40{\%} to 0.95{\%}), and the RR of ATEs was 1.36 (95{\%} CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.",
author = "Tracy Proverbs-Singh and Chiu, {Sophia K.} and Ziyue Liu and Sonia Seng and Guru Sonpavde and Choueiri, {Toni K.} and Tsao, {Che Kai} and Menggang Yu and Noah Hahn and Oh, {William K.} and Galsky, {Matthew D.}",
year = "2012",
month = "12",
doi = "10.1093/jnci/djs435",
language = "English (US)",
volume = "104",
pages = "1837--1840",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Arterial thromboembolism in cancer patients treated with cisplatin

T2 - A systematic review and meta-analysis

AU - Proverbs-Singh, Tracy

AU - Chiu, Sophia K.

AU - Liu, Ziyue

AU - Seng, Sonia

AU - Sonpavde, Guru

AU - Choueiri, Toni K.

AU - Tsao, Che Kai

AU - Yu, Menggang

AU - Hahn, Noah

AU - Oh, William K.

AU - Galsky, Matthew D.

PY - 2012/12

Y1 - 2012/12

N2 - Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

AB - Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

UR - http://www.scopus.com/inward/record.url?scp=84870918725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870918725&partnerID=8YFLogxK

U2 - 10.1093/jnci/djs435

DO - 10.1093/jnci/djs435

M3 - Article

VL - 104

SP - 1837

EP - 1840

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 23

ER -